Resignation of CFO
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.7 pts more than Nifty Microcap 250 and 4.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Kabra Drugs Ltd has announced that Mr. Bangalore Venkatakrishnappa Ananth Kumar has resigned as the Chief Financial Officer (CFO) and Key Managerial Personnel of the company with effect from 08th October 2025. Simultaneously, the Board of Directors, based on recommendations of the Nomination and Remuneration Committee and Audit Committee, has appointed Mr. T. Pavanasam as the new CFO and KMP with effect from the same date. Mr. T. Pavanasam is a Commerce Graduate with over 15 years of experience in finance, taxation, and allied laws across diverse industries. The transition was approved at a Board meeting held on 08th October 2025 and disclosed under SEBI Listing Regulations.
This is a routine CFO transition with no stated reason for the outgoing CFO's departure. While the new appointee brings relevant finance and taxation experience, investors should monitor whether further disclosures clarify the circumstances of the previous CFO's exit.